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Biomarkers have dramatically impacted the way heart failure (HF) patients are eval-
uated and managed. A biomarker is a characteristic that is objectively measured and
evaluated as an indicator of normal biological or pathogenic processes, or pharmacologi-
cal responses to a therapeutic intervention. Natriuretic peptides [B-type natriuretic pep-
tide (BNP) and N-terminal proBNP] are the gold standard biomarkers in determining the
diagnosis and prognosis of HF, and a natriuretic peptide-guided HF management looks
promising. In the last few years, an array of additional biomarkers has emerged, each
reflecting different pathophysiological processes in the development and progression of
HF: myocardial insult, inflammation, fibrosis, and remodelling, but their role in the clini-
cal care of the patient is still partially defined and more studies are needed before to
be well validated. Moreover, several new biomarkers have the potential to identify
patients with early renal dysfunction and appear to have promise to help the manage-
ment cardio-renal syndrome. With different biomarkers reflecting HF presence, the vari-
ous pathways involved in its progression, as well as identifying unique treatment options
for HF management, a closer cardiologist-laboratory link, with a multi-biomarker
approach to the HF patient, is not far ahead, allowing the unique opportunity for specif-
ically tailoring care to the individual pathological phenotype.
Heart failure (HF) is a complex syndrome involving neuro-
humoral and inflammatory changes of different cell types
including cardiac myocytes, fibroblasts, endothelial, and
vascular smooth muscle cells. A consequence of the com-
plex pathophysiological substrate of HF is the ever increas-
ing number of circulating molecules (i.e. biomarkers)
found/discovered to be altered in patients with HF.
Many molecules have been labelled as circulating ‘bio-
markers’ in HF. The present document aims at helping the
clinician in (i) appropriately using available biomarkers,
and (ii) approaching new biomarkers through the literature
with a critical attitude. Of all biomarkers reported to pro-
vide original information in diagnosis, prognosis, or man-
agement of HF, only cardiac troponins I or Tand natriuretic
peptides are cardio-specific. This explains why the largest
body of evidence supporting their clinical use has been col-
lected on these two families of biomarkers.
Background
The consensus document for Italian clinical cardiologists
has been published very recently, where the evidence on
the use of troponins and natriuretic peptides in HF are
reported in several sections.1
The present document does not aim at comprehensively
reviewing all established and candidate laboratory bio-
markers in HF. Other types of biomarkers, such as imaging
or genetic biomarkers, will not be discussed in detail, but
will be evaluated in comparison with laboratory bio-
markers. Unless otherwise specified, ‘biomarkers’ will be
used for ‘circulating biomarkers’ or ‘laboratory bio-
markers’ throughout the present document.
Objectives
Aims of the present review are
(1) To summarize the evidence supporting the clinical
use of cardiac specific biomarkers, the main
issue being how to make a good use of these vali-
dated markers in specific clinical/ambulatory
settings.
(2) To provide the interested clinician with concise,
essential information on the so-called ‘new bio-
markers’ in order to help them in a critical use of
the literature.
Premises
Before dealing with individual biomarkers, grouped by
‘reasonable’ categories, a general agreement on the fol-
lowing twomethodological issues should be reached:
(1) Assays of the biomarkers;
(2) Sample size of studies to assess clinical perform-
ance of biomarkers.
Analytical issues
The contribution of the laboratory to the clinical manage-
ment of HF by the biomarkers, represents one of the most
important breakthroughs of the last decades.
Standardization and validation of diagnostic methods,
combined with a close link between the laboratory and the
clinic improves the confidence of the cardiologist in the
use and in a correct interpretation of analytical results on
circulating biomarkers.
Cardiovascular biomarkers are usually measured with
non-competitive immunometric assays in clinical labora-
tory practice.2 Analytical performance of biomarker labo-
ratory tests has progressively improved in the last 20 years.
In particular, the last generation of immunometric assays
using automated platforms is able to measure circulating
levels of biomarkers [such as B-type natriuretic peptide
(BNP), N-terminal proBNP (NT-proBNP), cTnI, and cTnT]
with a limit of detection (LoD) of few ng/L (from 1ng/L to
5ng/L), a limit of quantification (LoQ) ! 10 CV% in the
range of 5–15ng/L, and a turn round time (TAT) of less than
30min.2 These very good analytical performances allowed
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the use of these biomarkers as favourite methods even in
the emergency department. Despite this remarkable
increase in analytical performances, these immunoassays
still suffer significant systematic differences between the
biomarkers values measured by commercially available
laboratory tests, especially for BNP2,3 and cTnI4 methods.
Accordingly, clinicians should take great care in comparing
results obtained by laboratories using different methods.
More difficulties are to be expected from point-of-care
testing (POCT), whose reliability is, at the present time, not
always adequately optimized and evaluated.5 As far as the
POCT methods for cardiac troponins are concerned, it is
important to consider that the commercial methods so far
available, do not satisfy the analytical quality specifications
recommended by the international guidelines.6–8 The POCT
methods usually measure the recommended upper limit of
normal with an error > 20% CV and so they should be used
for rule-in and rule-out of myocardial infarction only where
(or when) the more sensitive immunoassay methods using
automated platforms are not available.8 As far as the POCT
methods for the measurement of natriuretic peptides are
concerned, these assays are often used in both emergency
departments and primary care, although their analytical
sensitivity and reproducibility is lower than that of immuno-
assaymethods using automated platforms.9–11
Sample size
It is common belief that sample size calculations, in order
to minimize the risk of false-negative results, are the mat-
ter of clinical trials testing drugs. This is definitely wrong,
since the same risk is inherent in studies assessing predic-
tive value or associations of risk factors, such as bio-
markers. Without an adequate power, say above 60%, the
risk of a false negative result is too high to reject the null
hypothesis. The same is true for positive results obtained in
small samples, too susceptible of bias and play of chance to
be translated into clinical practice.
An authoritative example of power calculation is pro-
vided by an analysis of Framingham on renin. Given the
lack of a significant association of renin with cardiovascular
risk, the statistical power to detect modest effects was
assessed. At an alpha of 0.05, the power was at least 80%
for each outcome (hard cardiovascular disease and all-
cause mortality), in the full sample and in the hypertensive
sub-sample, for the true HRof 1.25 per SD of log-renin.12
The data reported in Table 1, considering different com-
binations of hazard ratios and power, provide an idea on
the number of patients needed for a reliable assessment of
association between biomarkers and risk.
Myocardial stress and function laboratory
biomarkers
Pathophysiological and clinical interpretation
HF is considered the fatal finishing line of all cardiovascular
disorders. HF is a clinical syndrome characterized by typi-
cal symptoms (e.g. breathlessness, ankle swelling, and
fatigue) that may be accompanied by signs (e.g. elevated
jugular venous pressure, pulmonary crackles, and periph-
eral oedema) caused by a structural and/or functional
cardiac abnormality, resulting in a reduced cardiac output
and/or elevated intra-cardiac pressures at rest or during
stress.13 Positive history and some physical signs (such as
orthopnoea, rales, third heart sound, or jugular vein dis-
tension) share a good diagnostic specificity, but also a poor
sensitivity in diagnosing acute congestive HF (Table 2).13,14
Therefore, the diagnosis of both acute and chronic HF is
based on the clinical judgment including a combination of
history, physical examination, and appropriate investiga-
tions, as recommended by all international guidelines.15–19
The pathophysiological interpretation of plasma BNP/
NT-proBNP variations may be difficult in some clinical set-
tings. The cardiac endocrine function has a pivotal role in
the regulation of body fluids, electrolytes, and
haemodynamics.20 The cardiac peptide hormones, ANP and
BNP, share diuretic, natriuretic, vasodilating, and anti-
hypertrophic activities.20 A continuous and intense infor-
mation exchange flows from the endocrine heart system to
nervous and immunological systems and to other organs,
including kidney, endocrine glands, liver, adipose tissue,
immune-competent cells, and vice versa. This close link
between cardiac natriuretic peptide system and counter-
regulatory systemswith sodium-retentive, vasoconstrictive
and hypertrophic activities (including renin-angiotensin-
aldosterone system, endothelins, catecholamines,
arginine-vasopressine system, and pro-inflammatory cyto-
kines) may explain the increase in circulating levels of
Table 2 Accuracy of history and physical findings in diagnos-
ing acute congestive heart failure (modified from references
13 and 14)
Variable Sensitivity Specificity Accuracy
History of HF 62 94 80
Dyspnea 56 53 54
Orthopnoea 47 88 72
Rales 56 80 70
Third heart sound 20 90 66
Jugular vein distension 39 94 72
Oedema 67 68 68
HR, heart failure.
Table 1 Number of patients to be enrolled in studies testing
prognostic value of biomarkers. Different calculations are
presented according to power (type II error) and impact on
outcomes expressed as hazard ratio (HR) of above vs below
the median level of the biomarker
HR Sample size Power
1.2 4240 80%
1.4 1192 80%
1.6 580 80%
1.2 3334 70%
1.4 937 70%
1.6 457 70%
HR, hazard ratio.
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BNP/NT-proBNP in patients with some extra-cardiac
diseases.20
A deficiency in biological action of circulating cardiac
natriuretic peptide hormones may contribute to explain
the altered electrolyte and fluid balance occurring in
chronic HF: a phenomenon, defined as the ‘endocrine par-
adox’ of HF.20 Patients with congestive HF show signs of
fluid retention and vasoconstriction, despite the extremely
high circulating BNP levels, measured by immunoassay
methods at present time commercially available.1,20
Indeed, a blunted natriuretic response after pharmacologi-
cal doses of ANP and BNP has been observed in experimen-
tal models and in patients with chronic HF, suggesting a
resistance to the biological effects of natriuretic
peptides.20 An explanation of the paradox of high circulat-
ing levels of the hormone, but low plasma natriuretic activ-
ity may be the large cross-reactivity of proBNP on the
immunoassay methods considered specific for BNP.1,21 This
cross-reaction produces a great overestimation of the
measured levels of BNP, because proBNP is the predomi-
nant peptide form present in plasma of patients with
severe HF.1,20 Another cause of resistance to biological
action of natriuretic peptides is that proBNP is able to bind
to the natriuretic peptide receptors, but it stimulates the
receptor with lower potency than the active hormones,
ANP and BNP, and so it produces a decrease in natriuretic
activity by displacing the more biologically active peptide
hormones from the receptors.22
Another important clinical issue in the interpretation of
measurements of natriuretic peptides in HF is that circulat-
ing BNP and NT-proBNP levels mirror the effectiveness of
the treatment of acute or chronic HF, with lowering of lev-
els over time associatedwith better clinical outcomes.23–26
Use of BNP/NT-proBNP in clinical diagnosis of
acute and chronic heart failure
All the most recent national and international guide-
lines13,16–20 recommend the natriuretic peptides, and in
particular the peptides related to the B-type cardiac pep-
tide hormone (such as BNP and NT-proBNP), as the first line
biomarkers for the diagnosis of both acute and chronic HF.
In particular, the 2013 ACCF/AHA guidelines recommend
the BNP and NT-proBNP measurement for the diagnosis or
exclusion of HF in patients with chronic or acute decom-
pensated HF (with the maximum degree of class of recom-
mendation I and level of evidence A).16 The clinical
contribution to the diagnosis of BNP/NT-proBNP assay is
particularly significant when the etiology of dyspnoea is
unclear. Moreover, the 2013 ACCF/AHA guidelines recom-
mend the measurement of natriuretic peptides with the
maximum degree of evidence (class I and level A) also for
the prognosis of HF patient.16
Usually there are no differences in the diagnostic use of
BNP and NT-proBNP immunoassays.1 However, two recent
studies from the PARADIGM-HF (prospective comparison of
angiotensin II receptor blocker neprilysin inhibitor (ARNI)
with angiotensin-converting-enzyme inhibitor (ACEI) to
determine impact on global mortality and morbidity in
heart failure (HF)] trial27,28 reported conflicting results
between BNP and NT-proBNP levels. PARADIGM-HF study
evaluated the clinical effects of a new drug (denominated
LCZ696 or ENTRESTO), including a combination of sacubi-
tril, a neprilysin (NEP) inhibitor, and valsartan, an angio-
tensin II receptor blocker. The mechanism of of action of
this drug is complex, combining the effect of the angioten-
sin II receptor blocker and that of the neprilysin inhibitor.
The enzyme neprilysin causes degradation not only of
natriuretic peptides but also of a variety of components
affecting the mechanisms of action for several other circu-
lating hormones, including adrenomedullin, bradykinins,
angiotensin I, endothelin-1, and substance P.29 The ration-
ale for the use of a drug containing a neprilysin inhibitor in
HF patients is that this proteolytic enzyme can degrade the
biologically active natriuretic peptides (ANP, BNP, and
CNP).29 For this reason, a drug, containing a substance
inhibiting natriuretic peptide degradation (such as
LCZ696), may increase the circulating levels of the biologi-
cally active natriuretic hormones and, by doing so, may
improve the clinical conditions of HF patients by increasing
diuresis and natriuresis and reducing cardiac stress.29
PARADIGM-HF study found that plasma BNP levels were
higher during treatment with LCZ696 than with enalapril,
but, on the contrary, circulating levels of NT-proBNP and
cardiac troponin T (cTnT) were lower during treatment
with LCZ696 than with enalapril in the first week of
treatment.27 Authors explained these conflicting results
obtained in the PARADIGM-HF study by considering the
combined action of LCZ696 drug. Indeed, BNP (but not NT-
proBNP) is a substrate for neprilysin29,30; as a result, the
increase in BNP levels should reflect the inhibiting action
of the drug on the enzyme neprilysin. On the contrary, the
decrease in NT-proBNP levels may reflect the beneficial
effects of the drug on myocardial function and vascular
haemodynamics, especially by inhibiting the renin-
angiotensin-aldosterone system activity.29,30 Indeed, the
reduction of cardiac stress during LCZ696 treatment should
reduce the production and secretion of natriuretic pepti-
des from cardiomyocytes (and so a fall of the circulating
levels of NT-proBNP, too).1 In conclusion, clinicians should
accurately consider the clinical setting in order to correctly
interpret the variations of natriuretic peptides measured
by commercially available laboratory methods. In particu-
lar, clinicians should distinguish the increase in BNP levels,
due to the inhibiting effect of LCZ696 from those due to
deterioration of clinical conditions.
Several studies, including also several meta-analyses,31–37
demonstrated the clinical relevance of BNP/NT-proBNP
assay in patients with both acute and chronic HF in different
clinical settings (including emergency department and pri-
mary care). The measurement of BNP and NT-proBNP is use-
ful in supporting clinical judgment for the diagnosis or
exclusion of HF in the setting of chronic ambulatory HF or
acute decompensated HF (with the maximum degree of
class of recommendation I and level of evidence A).16
Indeed, all international guidelines, starting from the first
years of this century, state that lower values of BNP or NT-
proBNP actually exclude the presence of HF, while higher
values have reasonably high positive predictive value to
diagnose HF.13,16–19,38–41 Therefore, BNP/NT-proBNP assay is
recommended for ruling-out HF, but not to establish the
diagnosis.13 Although some international guidelines13,17–19
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suggest some cut-off values of BNP assay for the ruling-out
or ruling-in HF, these values are only indicative, because
there are large systematic between BNP immunoassaymeth-
ods.2,3 On the contrary, the cut-off values reported by inter-
national guidelines for NT-proBNP assay are more reliable,
because only one manufacturer distributes the standard and
materials for all immunoassay methods, commercially avail-
able in Europe for NT-proBNPmeasurement.2,3
BNP/NT-proBNP assay can be also useful for detection of
early phases of HF (phase A or B),16,40 when patients are
still asymptomatic or pauci symptomatic (functional NYHA
classes I and II).42 BNP/NT-proBNP assay cannot differenti-
ate the type of cardiac dysfunction (systolic vs. diastolic);
however, the BNP/NT-proBNP levels found in HF patients
with preserved left ventricular ejection fraction usually
are lower than those of HF patients with reduced left ven-
tricular ejection fraction.13,36 As recommended by national
and international guidelines,13,16–19,38–41 the clinical infor-
mation obtained from electrocardiographic and echocar-
diographic examination and from the BNP/NTproBNP assay
are not equivalent, but they contribute independently to
the HF diagnosis and to the definition of the patient’s clini-
cal status.
At present time, with the exception of cardiac natriu-
retic peptides, no other cardiovascular biomarkers are rec-
ommended by international guidelines for the diagnosis of
both acute and chronic HF with the maximum degree of
class of recommendation and level of evidence.13,16–19
Synthesis of evidences
(1) The measurement of cardiac natriuretic peptides is
recommended for the diagnosis of HF in patients
with dyspnoea by national and international guide-
lines since year 2005.
(2) Due to the high degree of clinical sensitivity and
negative predictive value, the measurement of car-
diac natriuretic peptides is useful for excluding the
diagnosis of HF, especially using method-specific
reference limits and taking into account sex and
age of the patient as well as the presence of obe-
sity and kidney failure.
(3) The measurement of cardiac natriuretic peptides
cannot differentiate the type of cardiac dysfunction
(systolic vs. diastolic).
(4) The clinical information obtained from echocardio-
graphic examination and from BNP/NT-proBNP assay
is not equivalent, but they contribute independ-
ently to the HF diagnosis and to the definition of
the patient’s clinical status.
Clinical use of cardiac natriuretic peptides as
prognostic biomarkers in heart failure patients
More than 1000 published studies, including several meta-
analyses,43–56 evaluated the prognostic accuracy of natriu-
retic peptides (in particular BNP and NT-proBNP) in patients
with acute or chronic HF. Plasma BNP and NT-proBNP levels
usually decrease during treatment of chronic HF, correlating
with improved clinical outcomes, including mortality, hospi-
tal stay and/or readmission rate.15,24,25,41,43–47,48,51–54,56–60
According to these experimental and clinical evidences,
measurement of natriuretic peptides is recommended with
the maximum score (class I and level A) for prognosis in both
ambulatory and acute HF patient by the 2013 AACF/AHA
guidelines for themanagement of HF.16
Synthesis of evidences
(1) Cardiac natriuretic peptides measurement is rec-
ommended for risk stratification in all patients with
acute and chronic HF.
(2) The short- and long-term risk of death and of cardi-
ovascular events increases gradually with the
increase of biomarker values, even for BNP and NT-
proBNP levels within the normal range.
(3) The prognostic information provided by the cardiac
natriuretic peptides is independent of that provided
by other known cardiovascular risk factors and is
associated additively with that of cardiac troponins
and cardiac fibrosis markers, such as galectin-3 and
sST2 protein.
Use of cardiac natriuretic peptides in clinical
management of HF patients
There is an increasing consensus about the use of natriu-
retic peptide-guided HF management.26 Several clinical
trials and meta-analyses23–25,43–56,58–60 demonstrated that
either baseline level of BNP and NT-proBNP or its decrease
after treatment hold a powerful prognostic value in HF
patients. In particular, the decrease in peptide natriuretic
levels during treatment is associated with clinical improve-
ment, whereas unchanged or increased levels are associ-
ated with disease progression and worse prognosis.23–26
The rationale for the use of BNP-guided treatment is that
the variation in plasma peptide concentrations before and
after a period of standard therapy is able to distinguish
‘responders’ with a better prognosis (i.e. a decrease> 30%
in peptide levels after therapy), from ‘non-responders’
patients with a more severe prognosis (i.e. not decrease or
even increase in peptide levels after therapy), who prob-
ably need both a re-evaluation of clinical status and a re-
assessment of treatment.16,26,45 Moreover, it is important
to note that the rationale for the use of natriuretic
peptide-guided HF management is based also on the
assumption that laboratory tests are able to accurately
assess the true status of the cardiac endocrine function.2,20
Despite this large number of experimental and clinical
evidences found in the literature,23–25,43–56,58–60 the interna-
tional guidelines still report an interlocutory judgement
about the natriuretic peptide-guided HF management. It
should be recognized that evidence is not based on a single,
well designed, adequately sized phase III trial. The ESC 2016
guidelines13 provide only some general recommendations
about the usefulness of the natriuretic peptides as a guide-
to therapy. In particular, it is recommended to begin treat-
ment with valsartan-sacubitril only in patients with high lev-
els of natriuretic peptides. The 2013 ACCF/AHA guidelines16
recommended that the dosage of BNP or NT-proBNP to opti-
mize the therapy should be limited to euvolaemic patients
and in the context of a well-structured program of manage-
ment of chronic HF (class of evidence: IIa, level of evidence:
B). As for acute HF, the effectiveness of therapy guided by
natriuretic peptides has low levels of recommendation and
evidence (class of evidence: class IIb, level of evidence: C
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type).16 The NICE guidelines19 summarize the evidence in
the literature and concluded that the use of natriuretic pep-
tides to guide treatment in chronic HF may lead to potential
reduction inmortality in some subgroups, although the over-
all usefulness in all HF patients remains uncertain.
Synthesis of evidences
(1) Patients who respond to treatment with a signifi-
cant decrease in circulating levels of BNP or NT-
proBNP have a better prognosis, particularly with
regard to the decrease of mortality and/or major
cardiovascular events.
(2) BNP/NT-proBNP guided therapy significantly
reduces mortality in patients younger than 75 years
while hospitalization is reduced for all ages and for
all causes of hospitalization.
(3) In light of the current scientific evidence, it is
appropriate to measure the BNP/NT-proBNP levels
in patients hospitalized for acute HF at least at the
admission and before the discharge to assess the
patient’s response to therapy. A reduction in levels
greater than 30% should be considered significant.
(4) There is no evidence in the literature regarding the
serial evaluation of BNP/NT-proBNP during hospital-
ization (except for the admission and discharge)
Laboratory biomarkers of myocardial injury
Pathophysiological and clinical interpretation of
myocardial release of troponin in heart failure
patients
Cardiac troponin I (cTnI) and cTnTare the most widely used
biomarkers of myocardial injury in clinical research and in
patients with acute coronary syndromes.1,2 More recently,
the availability of highly sensitive assays has markedly
increased the analytical sensitivity, thus allowing tomonitor
also the majority of patients with stable chronic HF, whose
concentrations of troponins were often below the LoD of
earlier generation assays.61–64 cTnI and cTnTare essentially
equivalent as markers of cardiac injury in HF patients. In
virtually all HF patients, highly sensitive methods can meas-
ure circulating cTnI and cTnT levels above their respective
limits of detection. In particular, patients with HF, aged 70
years or more, often have circulating concentrations of cTnI
and cTnT assayed with high sensitivity methods above the
decision limit (99th percentile in a reference population of
apparently healthy individuals).61–64
From an analytical point of view, some important issues
should be discussed in detail, regarding the analytical sensi-
tivity and specificity of laboratory tests at present
employed for cTnI and cTnTmeasurement. First, it is impor-
tant to accurately define the analytical specifications char-
acterizing the highly sensitive methods.66,67 One should
define methods with high sensitivity only the immunoassays
that measure the 99th percentile of the distribution of pro-
teins cTnI and cTnT in the reference population (99th ULN)
with an error (expressed as coefficient of variation, CV)
equal to or lower than 10%,66,67 as required by all the most
international guidelines, including the Third Universal
Definition of Myocardial Infarction.6 The methods showing
an intermediate imprecision (10–20%) should be considered
clinically usable (but not highly sensitive methods).6–8,66,67
The reference population on which the 99th URL value is
calculated should consist of at least 300 apparently healthy
subjects of both genders with a broad age distribution (usu-
ally from 18 to 70 years).7,66,67 It is important to note that
highly sensitive immunoassay methods should also measure
the levels of cTnI and cTnT in the majority (i.e. >50%) of
apparently healthy adults, who compose the reference pop-
ulation. In particular, the most sensitive, commercially
available in Europe, cTnI method is able to measure tropo-
nin levels above the detection limit in the great majority
(>95%) of healthy subjects,66,67 also including neonates,
children, and adolescents.68,69 Second, as far as the cardio-
specificity of cardiac troponin immunoassaymethods is con-
cerned, recent studies suggested that the cTnT may be re-
expressed in skeletal myocytes of patients with awide spec-
trum of neuromuscular diseases in the absence of clinical
and cTnI evidence of myocardial injury.70–75 Although cTnT
and cTnI are both absent in healthy adult skeletal muscle,
cTnT (but not cTnI) is present in foetal skeletal muscle. The
injured skeletal muscle repairs itself by regeneration; this
process recapitulates embryonic myogenesis, and so
patients with chronic neuro-muscular diseases can present
increased circulating levels of cTnT, but not of cTnI.70–72
From a clinical point of view, it is important to note that
cTnT circulating levels may be increased above the 99th
URL value in patients with neuromuscular diseases.74,75
Furthermore, heart involvement can be excluded by normal
values of ECG, echocardiogram, and BNP/NT-proBNP levels.
However, to exclude myocardial injury in this group of
patients it may be preferable to measure also the cTnI con-
centration using a high-sensitive method.74
Prognostic relevance of cardiac troponins
Several studies demonstrated that increased circulating
levels of cTnI and cTnT, especially when these biomarkers
are measured with highly sensitive methods, are found in
patients with HF, who often do not present obviousmyocar-
dial ischemia or underlying coronary artery disease.61–64
These findings61–64 suggest that increased cTnI and cTnT in
these patients could be caused by cardiomyocyte injury or
necrosis. In chronic or acute decompensated HF, elevated
cardiac troponin levels are associated with worse clinical
outcomes and/or mortality.61–64,76–83 Indeed, HF patients,
showing a significant and lasting decrease in troponin levels
after appropriate pharmacological treatment have a better
prognosis compared with those who did not show any or
only a transient decrease.61,76–83 Based on these results,
2013 AACF/AHA guidelines for the management of HF rec-
ommend that troponin I or T be routinely measured, in
addition to natriuretic peptides, in both acute and ambula-
tory HF patients for improving risk stratification, with the
maximum degree of evidence (class I and level A).16
According to the guidelines by the Heart Failure Section of
the Third Universal Definition of Myocardial Infarction
Global Task Force, clinicians should be aware of the high
frequency of troponin elevation in patients with HF, and for
this reason they should keep in mind the possible causes of
this phenomenon, and, independent of AMI diagnosis.84
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Synthesis of evidences
(1) Increasing circulating levels of plasma cardiac tro-
ponin, even within a normal range, are associated
with a worse prognosis in HF.
(2) The prognostic value of cardiac troponins is inde-
pendent and incremental compared with other risk
factors and cardiovascular biomarkers
Laboratory biomarkers of cardiac
remodelling and fibrosis
Cardiac ventricular remodelling occurs progressively
in untreated patients after large myocardial infarction and
in those with cardiomyopathy. Myocardial remodelling in
ischaemic and non-ischaemic cardiomyopathies involves
not only the cardiomyocytes, but also non-myocyte cells
and the extracellular matrix, which includes fluid, colla-
gen, and glycoproteins.85,86 Detection of fibrosis and of an
ongoing remodelling process holds clinical value and should
guide therapeutic strategy in HF patients. For this reason,
there is an increasing interest in the development of new
biomarkers and a great number of laboratory tests have
been recently proposed, whose clinical usefulness, how-
ever, is not fully established yet.86 Fibrosis is an ubiquitous
mechanism of tissue repair. An increase in cardiac fibrosis
is associated not only to normal ageing but also to arterial
hypertension and other less common diseases. An excessive
collagen synthesis and deposition and/or a decrease in its
degradation cause an increase in collagen content of myo-
cardium and blood vessel wall which can lead to cardiac
dysfunction and ultimately cardiac failure. Part of the ben-
eficial effect of recommended therapies for HF may be
explained by their anti-fibrotic action. At present, there
are no reliable markers with sufficient sensitivity and
cardiac-specificity to be used clinically in HF patients.
However, many studies, even including some recent
meta-analyses,86–89 have been published on biomarkers of
cardiac remodelling and fibrosis, especially concerning
galectin-3 and sST2, in patients with acute and chronic HF.
However, the evidence available is not sufficient to support
their use in the clinical routine to improve prognostic strati-
fication and diagnosis of individual patients.16,86 In particu-
lar, more studies are needed to document the independent
prognostic value of circulating markers of fibrosis, on top of
the other established markers, cardiac troponins and natriu-
retic peptides.13,16,86 Being non-cardiac-specific bio-
markers, the value of galectin-3 and sST2 in HF patients
should be established in front of other frequent comorbid-
ities, such as diabetes, systemic chronic inflammatory disor-
ders, renal and liver diseases.13,86
The 2016 ESC guidelines13 mention the increasing inter-
est in ‘new’ biomarkers of HF, but underscore that the evi-
dence currently available is not sufficient to recommend
their use in clinical practice. On the contrary, the 2013
American College of Cardiology Foundation (ACCF)/
American Heart Association (AHA) guidelines16 contain rec-
ommendations on biomarkers of inflammation and fibrosis,
suggesting that the most promising biomarkers of this class
are galectin-3 and soluble ST2. Even with the low level of
recommendation, the 2013 ACCF/AHA guidelines suggest
that the dosage of biomarkers of inflammation and fibrosis,
along with the dosage of other biomarkers, may improve
the prognostic stratification both in patients with chronic
(class of evidence: IIb, level of evidence: B) and acute HF
(class of evidence: IIb, level of evidence: A).16
Synthesis of evidences
(1) There are still some doubts on efficiency, prognos-
tic role, and cost-effectiveness of biomarkers of
cardiac remodelling and myocardial fibrosis, even if
many studies have been published recently.
(2) In particular, more studies are needed to confirm
their independent and additional prognostic contri-
bution in comparison with other biomarkers, such
as natriuretic peptides and cardiac troponins.
(3) Moreover, they are non-cardio-specific biomarkers and
their usefulness has to be fully established in the pres-
ence of co-morbidities such as diabetes, chronic sys-
temic inflammatory diseases, renal and liver diseases.
(4) Considering the wide range of biomarkers of cardiac
remodelling and myocardial fibrosis, the clinician
should direct his decision remembering the analyti-
cal characteristics of the assay, the efficiency and
prognostic effectiveness of the biomarker also in
relation to patients’ setting, possible confounding
variables, co-morbidities and costs.
Novel biomarkers and multi-markers models
In recent decades, several multi-marker models (probably
more than 100) have been suggested and evaluated for dif-
ferent populations of HF patients.13,14,90–92 Criteria to evalu-
ate and compare the prognostic efficacy and efficiency of
new cardiovascular risk biomarkers were recently reported
and discussed in details.91,92 Novel risk biomarkers should be
evaluated in several phases, including initial proof of con-
cept, prospective validation in independent populations,
documentation of incremental information, when added to
standard riskmarkers, assessment of effects on patientman-
agement and outcomes, and ultimately, cost-
effectiveness.91,92 Biomarkers that do not change the man-
agement of a disease unlikely will significantly affect patient
outcome and therefore will not be cost-effective (judged in
terms of quality-adjusted life-years gained).14,91,92 The
search is still open for novel biomarkers useful for prognosis
and guide therapy in HF patients.14,26,93 Promising candidate
biomarker may be: growth differential factor-15 (GDF-
15),94–96 carbohydrate antigen-125 (CA-125),97–99 C-terminal
pro-vasopressin (copectin),100–103 mid-regional pro-
adrenomedullin (MR-proADM),100,101,104 NEP,30,105 and
orexin.93,106 Some of these molecules have been utilized for
many years as tumour-markers (CA-125), neuro-hormones
(copeptin, MR-proADM) or inflammatory markers (GDF-15) in
clinical practice. Therefore, several studies are available on
their biological activity and variation, pathophysiological
and clinical relevance, reference range values and analytical
characteristic of assay methods.93 Conversely, there are
scarce data on neprilysin30 and orexin,106–108 which should
be considered as biomarkers in the early discovery phase
and still under evaluation. A detailed discussion of that
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clinical relevance of these promising HF biomarkers is out of
the aim of this executive summary and interested readers
can consult the references formore information.
The relatively modest performance allowed by individual
biomarkers prompted several investigators to evaluate the
hypothesis whether multiple biomarkers could be combined
to improve prognostic performance.14,90–92 The ‘multimarker
approach’ has been tested in several studies, primarily with
the use of circulating biomarkers.14,90–92 There are fewer
data incorporating imaging into multimarker algorithms and
also few data on the use of circulating, genetic, and/or imag-
ing biomarkers in combination.14,90–92 Multivariable statisti-
cal models may be used to calculate some multivariable risk
scores.109 Multivariable risk scores may help predicting death
in patients with HF, but they remain less useful for the predic-
tion of subsequent HF hospitalizations.13 A systematic review
examining 64 prognostic models along with a meta-analysis
andmeta-regression study of 117 prognostic models reported
only a moderate accuracy of models predicting mortality,
whereas models designed to predict the combined endpoint
of death or hospitalization, or only hospitalization, showed a
poorer prognostic power.110
Synthesis of evidences
(1) There are several novel biomarkers for prognosis and
to guide therapy in HF patients, which are in the
early discovery phase and still under evaluation.
(2) More studies are needed to evaluate the clinical
relevance and especially to confirm the independ-
ent and additional prognostic contribution of novel
biomarkers in comparison with natriuretic peptides
and cardiac troponins.
(3) Multivariable risk scores may help predicting death in
patients with HF, but at present time they remain less
useful for the prediction of subsequent HF hospitaliza-
tions or to guide therapy in the individual patient.
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